Business
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major d...
About this update from Neurothera Labs Inc.
[{"type":"text","content":"Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy\nInnovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030 Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment blends Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced via its partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC). The patent filing underscores the potential promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally. Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including SSRIs and other conventional options. About Clearmind Medicine Inc. Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol \"CMND.\" For further information, visit: https:...